Zobrazeno 1 - 10
of 486
pro vyhledávání: '"icosapent ethyl"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Indian Heart Journal, Vol 76, Iss , Pp S130-S137 (2024)
Indians have a pattern of atherogenic dyslipidaemia characterised by not so high LDL-C but elevated small, dense LDL-C, elevated triglyceride levels and low HDL-C levels. In addition, different lipid-lowering drugs exhibit pharmacokinetic variability
Externí odkaz:
https://doaj.org/article/b0e5b4b322be44e39bb3dd3f090058c8
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
IntroductionCardiovascular (CV) disease remains a leading cause of mortality despite statin therapy. Statin add-on lipid-lowering therapies have been investigated for CV risk reduction, but their effect on CV mortality has not been reviewed.MethodsTh
Externí odkaz:
https://doaj.org/article/33f9c1e2416b4c2b89831e36bec30ea6
Publikováno v:
Archives of Medical Science, Vol 19, Iss 6, Pp 1901-1903 (2023)
Introduction We determined eligibility for icosapent ethyl (EPA) treatment in coronary artery disease (CAD). Material and methods Consecutive patients with type 2 diabetes and CAD were prospectively included from 03/2019 to 12/2020. Results 574 pat
Externí odkaz:
https://doaj.org/article/074e0c09d59e48f69b6a9680f23af9dd
Autor:
Zhen Wang, Xin Zhang, Yanling Qu, Shuyang Zhang, Yundai Chen, Xiaoping Chen, Xin Qi, Peijing Liu, Shuqin Liu, Shan Jiang, Ronghai Man, Liping He, Ling Wu, Zhanquan Li, Yijun Shang, Zhaohui Qiu, Feng Liu, Chenhong Xu, Chunlin Lai, Junbo Ge
Publikováno v:
Lipids in Health and Disease, Vol 22, Iss 1, Pp 1-12 (2023)
Abstract Objectives Eicosapentaenoic acid in its ethyl ester form is the single active component of icosapent ethyl (IPE). This study was a phase III, multi-center trial assessing the safety and efficiency of IPE for treating very high triglyceride (
Externí odkaz:
https://doaj.org/article/3a434ceefda84ee8bfeb1407063431ff
Publikováno v:
ClinicoEconomics and Outcomes Research, Vol Volume 15, Pp 295-308 (2023)
Jean Lachaine,1,2 Jean-Nicolas Charron,2 Jean C Gregoire,3 Robert A Hegele,4 Lawrence A Leiter5 1University of Montreal, Montreal, QC, Canada; 2PeriPharm Inc., Montreal, QC, Canada; 3Institut de cardiologie de Montréal, Montreal, QC, Canada; 4Robart
Externí odkaz:
https://doaj.org/article/6742bb7185f545988a542d69ec56e146
Autor:
Subodh Verma, Andrew Kosmopoulos, Deepak L. Bhatt, David Fitchett, Anne Pernille Ofstad, Christoph Wanner, Michaela Mattheus, Bernard Zinman, Patrick R. Lawler, Lawrence A. Leiter
Publikováno v:
American Journal of Preventive Cardiology, Vol 15, Iss , Pp 100510- (2023)
Objectives: REDUCE-IT showed that icosapent ethyl (IPE) improved cardiovascular (CV) outcomes in participants with established CV disease (CVD) or type 2 diabetes (T2D) and at least one additional risk factor plus mild-moderate hypertriglyceridemia a
Externí odkaz:
https://doaj.org/article/d083c1a8463845e48238f05fb086aa8d
Autor:
Peter P. Toth, Jean Ferrières, Max Waters, Martin Bødtker Mortensen, Nick S. R. Lan, Nathan D. Wong
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
Icosapent ethyl (IPE) is a purified eicosapentaenoic acid–only omega-3 fatty acid that significantly reduced cardiovascular (CV) events in patients receiving statins with established cardiovascular disease (CVD) and those with diabetes and addition
Externí odkaz:
https://doaj.org/article/addedc3ef14445b8864bc454821eac33
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Brian Olshansky, Deepak L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Ralph T. Doyle, Rebecca A. Juliano, Lixia Jiao, Peter R. Kowey, James A. Reiffel, Jean‐Claude Tardif, Christie M. Ballantyne, Mina K. Chung
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 5 (2023)
Background In REDUCE‐IT (Reduction of Cardiovascular Events With Icosapent Ethyl–Intervention Trial), icosapent ethyl (IPE) versus placebo) reduced cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angin
Externí odkaz:
https://doaj.org/article/50b39d01ac344246a098267d5fb32c73